At S1P3, only fingolimod(P) was an S1P3 agonist, which is consistent with published reports [52] and may contribute to reported incidences of adverse events, such as increased blood pressure, decreased pulmonary function, and macular edema [22, 23, 24]. This evidence concerns the gene S1PR3 and macular retinal edema.